- Home
- PGP vs ONCY Comparison
PGP vs ONCY Comparison
Compare PGP & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PGP
- ONCY
- Stock Information
- Founded
- PGP 2003
- ONCY 1998
- Country
- PGP United States
- ONCY Canada
- Employees
- PGP N/A
- ONCY N/A
- Industry
- PGP Finance Companies
- ONCY Pharmaceuticals and Biotechnology
- Sector
- PGP Finance
- ONCY Health Care
- Exchange
- PGP Nasdaq
- ONCY Nasdaq
- Market Cap
- PGP 82.7M
- ONCY 49.1M
- IPO Year
- PGP N/A
- ONCY 1999
- Fundamental
- Price
- PGP $8.29
- ONCY $1.17
- Analyst Decision
- PGP
- ONCY Strong Buy
- Analyst Count
- PGP 0
- ONCY 4
- Target Price
- PGP N/A
- ONCY $4.33
- AVG Volume (30 Days)
- PGP 39.8K
- ONCY 1.6M
- Earning Date
- PGP 01-01-0001
- ONCY 07-31-2025
- Dividend Yield
- PGP 10.84%
- ONCY N/A
- EPS Growth
- PGP N/A
- ONCY N/A
- EPS
- PGP N/A
- ONCY N/A
- Revenue
- PGP N/A
- ONCY N/A
- Revenue This Year
- PGP N/A
- ONCY N/A
- Revenue Next Year
- PGP N/A
- ONCY N/A
- P/E Ratio
- PGP N/A
- ONCY N/A
- Revenue Growth
- PGP N/A
- ONCY N/A
- 52 Week Low
- PGP $5.83
- ONCY $0.33
- 52 Week High
- PGP $7.81
- ONCY $1.53
- Technical
- Relative Strength Index (RSI)
- PGP 58.08
- ONCY 75.27
- Support Level
- PGP $8.22
- ONCY $0.71
- Resistance Level
- PGP $8.42
- ONCY $1.31
- Average True Range (ATR)
- PGP 0.09
- ONCY 0.12
- MACD
- PGP 0.00
- ONCY 0.04
- Stochastic Oscillator
- PGP 62.05
- ONCY 81.33
About PGP Pimco Global StocksPlus & Income Fund of Beneficial Interest
PIMCO Global Stocksplus & Income Fund is a closed-end management investment company. The objective of the fund is to seek a total return comprised of current income, current gains, and long-term capital appreciation. The fund invests a majority of the fund's net assets in a combination of securities and instruments that provide exposure to stocks and or produce income.
About ONCY Oncolytics Biotech Inc.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.